1
|
Weiland F, Arentz G, Klingler-Hoffmann M, McCarthy P, Lokman NA, Kaur G, Oehler MK, Hoffmann P. Novel IEF Peptide Fractionation Method Reveals a Detailed Profile of N-Terminal Acetylation in Chemotherapy-Responsive and -Resistant Ovarian Cancer Cells. J Proteome Res 2016; 15:4073-4081. [DOI: 10.1021/acs.jproteome.6b00053] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Florian Weiland
- Adelaide
Proteomics Centre, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia 5005, Australia
- The Institute for Photonics & Advanced Sensing (IPAS), The University of Adelaide, Adelaide, South Australia 5005, Australia
| | - Georgia Arentz
- Adelaide
Proteomics Centre, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia 5005, Australia
- The Institute for Photonics & Advanced Sensing (IPAS), The University of Adelaide, Adelaide, South Australia 5005, Australia
| | - Manuela Klingler-Hoffmann
- Adelaide
Proteomics Centre, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia 5005, Australia
- The Institute for Photonics & Advanced Sensing (IPAS), The University of Adelaide, Adelaide, South Australia 5005, Australia
| | - Peter McCarthy
- Department
of Human Immunology, Centre for Cancer Biology, University of South Australia, Adelaide, South Australia 5000, Australia
| | - Noor A. Lokman
- Adelaide
Proteomics Centre, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia 5005, Australia
- Robinson
Institute, Research Centre for Reproductive Health, School of Paediatrics
and Reproductive Health, University of Adelaide, Adelaide, South Australia 5005, Australia
| | - Gurjeet Kaur
- Institute
for Research in Molecular Medicine, Universiti Sains Malaysia, 11800
Minden, Pulau Pinang, Malaysia
| | - Martin K. Oehler
- Adelaide
Proteomics Centre, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia 5005, Australia
- Robinson
Institute, Research Centre for Reproductive Health, School of Paediatrics
and Reproductive Health, University of Adelaide, Adelaide, South Australia 5005, Australia
- Department
of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide, South Australia 5005, Australia
| | - Peter Hoffmann
- Adelaide
Proteomics Centre, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia 5005, Australia
- The Institute for Photonics & Advanced Sensing (IPAS), The University of Adelaide, Adelaide, South Australia 5005, Australia
| |
Collapse
|
2
|
Tanaka KI, Ogo H, Kaji H, Miyatake K, Tokudome E, Sonoda K, Ogawa N, Asanuma M. Dipeptidyl compounds ameliorate the serum-deprivation-induced reduction in cell viability via the neurotrophin-activating effect in SH-SY5Y cells. Neurol Res 2013; 34:619-22. [DOI: 10.1179/1743132812y.0000000001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Affiliation(s)
- Ken-ichi Tanaka
- Department of Clinical PharmacyShujitsu University School of Pharmacy, Okayama, Japan
- Physiology and PharmacologySchool of Health and Social Services, Saitama Prefectural University, Saitama, Japan
| | - Hiroya Ogo
- Department of Clinical PharmacyShujitsu University School of Pharmacy, Okayama, Japan
- Department of Brain ScienceOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - Hiroaki Kaji
- Department of Clinical PharmacyShujitsu University School of Pharmacy, Okayama, Japan
- Department of BiochemistryHimeji Dokyo University School of Pharmacy, Hyogo, Japan
| | - Kaori Miyatake
- Department of Clinical PharmacyShujitsu University School of Pharmacy, Okayama, Japan
| | - Erika Tokudome
- Department of Clinical PharmacyShujitsu University School of Pharmacy, Okayama, Japan
| | - Kanako Sonoda
- Department of Clinical PharmacyShujitsu University School of Pharmacy, Okayama, Japan
- Department of Brain ScienceOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - Norio Ogawa
- Department of Brain ScienceOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - Masato Asanuma
- Department of Brain ScienceOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| |
Collapse
|
3
|
Neuroprotective and antiretroviral effects of the immunophilin ligand GPI 1046. J Neuroimmune Pharmacol 2007; 2:49-57. [PMID: 18040826 DOI: 10.1007/s11481-006-9060-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2006] [Accepted: 12/06/2006] [Indexed: 10/23/2022]
Abstract
HIV infection results in a neurodegenerative disorder for which currently there is no effective therapy available. Currently, available antiretroviral therapy has no impact on the production of early regulatory HIV proteins once the virus is integrated. Of these proteins, Tat was shown to be toxic to neurons. We, thus, used an in vitro neuronal culture system to determine if immunophilin ligands could protect against Tat-induced neurotoxicity. We found that GPI 1046 had potent neuroprotective effects in this model. The compound was able to protect the neurons even though it only partially obliterated Tat-induced oxidative stress in neurons, suggesting that other mechanisms may be important in mediating its neuroprotective effect. Furthermore, GPI 1046 showed inhibition of HIV replication and Tat-mediated long terminal repeat (LTR) activation suggesting that this class of compounds may be worthy of further exploration as a potential treatment for HIV dementia.
Collapse
|
4
|
Poulter MO, Payne KB, Steiner JP. Neuroimmunophilins: A novel drug therapy for the reversal of neurodegenerative disease? Neuroscience 2004; 128:1-6. [PMID: 15450348 DOI: 10.1016/j.neuroscience.2004.06.016] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/18/2004] [Indexed: 11/28/2022]
Abstract
Neuroimmunophilin ligands (NILs) are drugs derived from the immunosuppressant FK506 (tacrolimus) that have been shown to have variable efficacy in reversing neuronal degeneration and preventing cell death. In a wide range of animal models mimicking Parkinson's disease, dementia and even surgical nerve damage they induce re-sprouting, are neurotrophic or prevent nerve damage. The neurotrophic mechanism of action of these compounds is not known and may be dependent on the type of damage and genetic variability at the species or cellular level. Some evidence suggests that NILs may act through a family of proteins called FK506 binding proteins, some of which may regulate steroid hormone receptors. Other evidence suggests that NILs may protect neurons by upregulating the antioxidant glutathione and stimulating nerve regrowth by inducing the production of neurotrophic factors. Initial clinical trials have had mixed success. In one, patients with moderately severe Parkinson's disease showed no overall improvement in fine motor skills following 6 months of treatment by the neuroimmunophilin GPI 1485. But these patients did exhibit decreased loss of dopaminergic nerve terminals with a low dose of GPI 1485 and in fact some increase in dopaminergic terminals within 6 months of the higher dose of GPI 1485 drug treatment. As a result, a second phase II clinical trial using a patient population with less severe degeneration has been initiated concurrent with an investigation of GPI 1485 and other neuroprotective therapies funded by the National Institute of Neurological Disorders and Stroke. Another clinical trial ongoing at this time is exploring the use of a neuroimmunophilin ligand to prevent nerve degeneration and erectile dysfunction resulting from prostatectomy. In summary, neuroimmunophilins show promise to reverse some forms of neurodegeneration but exact factors that predict outcome have not been identified.
Collapse
Affiliation(s)
- M O Poulter
- Department of Psychology, Neuroscience Research Institute, Carleton University, 1125 Colonel By Drive, Ottawa, Ontario, Canada K1S 5B6.
| | | | | |
Collapse
|
5
|
Tanaka KI, Fujita N, Ogawa N. Immunosuppressive (FK506) and non-immunosuppressive (GPI1046) immunophilin ligands activate neurotrophic factors in the mouse brain. Brain Res 2003; 970:250-3. [PMID: 12706270 DOI: 10.1016/s0006-8993(03)02434-x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Based on the fact that several recent reports have indicated that non-immunosuppressive immunophilin ligands (IPLs) can activate neurite outgrowth or nerve regeneration, we investigated the neurotrophic factor-activating abilities of IPLs in vivo in order to clarify the molecular basis of neurotrophic-like activity. Both FK506 (an immunosuppressive IPL) and GPI1046 (a non-immunosuppressive IPL) significantly increased glial cell line-derived neurotrophic factor (GDNF) content in the substantia nigra. In addition, FK506 increased striatal brain-derived neurotrophic factor (BDNF) content significantly. Thus, our present results suggest that the molecular basis of IPL-induced neurotrophic-like activity may be dependent on GDNF and/or BDNF activation.
Collapse
Affiliation(s)
- Ken-ichi Tanaka
- Department of Brain Science, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikatacho, Japan.
| | | | | |
Collapse
|
6
|
Tanaka KI, Fujita N, Higashi Y, Ogawa N. Neuroprotective and antioxidant properties of FKBP-binding immunophilin ligands are independent on the FKBP12 pathway in human cells. Neurosci Lett 2002; 330:147-50. [PMID: 12231433 DOI: 10.1016/s0304-3940(02)00755-3] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We focused on immunophilin isoforms in order to clarify the neuroimmunophilins which were identified as targets for the immunophilin ligands to elicit a neuroprotective effect. Although the expressions of five FK506-binding protein (FKBP) mRNAs were detected in both SH-SY5Y (human neuroblastoma) and U251 (human glioma) cell lysates, the FKBP12 mRNA expression was detected in only the SH-SY5Y cells, and not the U251 cells. However, we found that the SH-SY5Y and the U251 cells were equipotent in the intensity of cellular protection of FK506 (an immunosuppressive immunophilin ligand) and GPI1046 (a non-immunosuppressive FK506 analog), indicating that the protective effect and glutathione activation of FK506 and GPI1046 had little need to bind FKBP12. Therefore, we conclude that the neuroprotective and antioxidant properties of immunophilin ligands are independent on the FKBP12 pathway.
Collapse
Affiliation(s)
- Ken-ichi Tanaka
- Department of Brain Science, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.
| | | | | | | |
Collapse
|
7
|
Tanaka KI, Yoshioka M, Miyazaki I, Fujita N, Ogawa N. GPI1046 prevents dopaminergic dysfunction by activating glutathione system in the mouse striatum. Neurosci Lett 2002; 321:45-8. [PMID: 11872253 DOI: 10.1016/s0304-3940(01)02547-2] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
We investigated both the antioxidant activities of GPI1046, a non-immunosuppressive derivative of FK506, and the in vivo neuroprotective properties against toxicity of intracerebroventricular 6-hydroxydopamine (6-OHDA) in mice. The 6-OHDA-induced reduction in dopamine and its metabolites in the striatum was significantly normalized by daily administration of GPI1046. Moreover, GPI1046 significantly reduced lipid peroxidation in vivo. Further, GPI1046 significantly increased striatal glutathione (GSH) levels by activating GSH synthesis, although the striatal catalase and superoxide dismutase activities did not change. We conclude that GPI1046 may have neuroprotective effects both in cell cultures and in vivo.
Collapse
Affiliation(s)
- Ken-ichi Tanaka
- Department of Brain Science, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikatacho, Okayama 700-8558, Japan.
| | | | | | | | | |
Collapse
|